SEC Form 4 · accession 0001140361-16-077194
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Abrams
Officer — Managing Director
Period of report
Aug 16, 2016
Accepted (ET)
Aug 18, 2016 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 16, 2016 | M | 14,178 | $0.3455 | A | 42,097 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.3455 | Aug 16, 2016 | M | 675 | A | Mar 30, 2008 | Apr 3, 2017 | Common Shares | 675 | 0 | D |
| Employee Stock Option (Right to Buy)F1 | $0.3455 | Aug 16, 2016 | M | 13,503 | A | Mar 30, 2008 | May 27, 2017 | Common Shares | 13,503 | 0 | D |
Explanation of responses
- F1The options were exeercisable at Cdn$0.4444; exercise price references above was converted into U.S. Dollars using an exchange rate of Cdn$1.2862=US$1.00.